ITOS insider transaction filings
iTeos Therapeutics, Inc. — 39 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-08-29. Screen ITOS transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for ITOS between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — iTeos Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-08-29 | 4 | Call Matthew — Chief Operating Officer | Code (U): 161,898 · Disposition to issuer (D): 9,063 (derivative) · Disposition to issuer (D): 135,937 (derivative) · Disposition to issuer (D): 41,694 (derivative) · Disposition to issuer (D): 66,170 (derivative) · Disposition to issuer (D): 17,074 (derivative) · +1 more | EDGAR |
| 2025-08-29 | 4 | Detheux Michel — Chief Executive Officer, Director | Code (U): 153,903 · Code (U): 94,027 · Disposition to issuer (D): 14,185 (derivative) · Disposition to issuer (D): 444,815 (derivative) · Disposition to issuer (D): 94,336 (derivative) · Disposition to issuer (D): 50,128 (derivative) · +3 more | EDGAR |
| 2025-08-29 | 4 | Lee David K — Director | Disposition to issuer (D): 21,141 (derivative) · Disposition to issuer (D): 23,625 (derivative) | EDGAR |
| 2025-08-29 | 4 | Feltquate David — Chief Medical Officer | Code (U): 47,000 | EDGAR |
| 2025-08-29 | 4 | Gall Matthew — Chief Financial Officer | Code (U): 89,429 · Disposition to issuer (D): 9,063 (derivative) · Disposition to issuer (D): 135,937 (derivative) · Disposition to issuer (D): 42,388 (derivative) · Disposition to issuer (D): 8,123 (derivative) · Disposition to issuer (D): 252,135 (derivative) | EDGAR |
| 2025-08-29 | 4 | McGrath Yvonne — Chief Scientific Officer | Code (U): 46,300 · Disposition to issuer (D): 91,000 (derivative) · Disposition to issuer (D): 69,069 (derivative) · Disposition to issuer (D): 16,054 (derivative) | EDGAR |
| 2025-08-29 | 4 | Hallal David — Director | Disposition to issuer (D): 25,140 (derivative) · Disposition to issuer (D): 146,160 (derivative) | EDGAR |
| 2025-08-29 | 4 | RHOADS ANN D — Director | Disposition to issuer (D): 27,178 (derivative) | EDGAR |
| 2025-06-11 | 4 | Detheux Michel — Chief Executive Officer | Option exercise (M): 8,400 @ $4.30 · Sale (S): 8,400 @ $10.03 · Option exercise (M): 43,882 @ $4.30 · Sale (S): 43,882 @ $10.03 · Option exercise (M): 8,400 @ $4.30 · Sale (S): 8,400 @ $10.02 · +10 more | EDGAR |
| 2025-06-06 | 4 | Detheux Michel — Chief Executive Officer | Option exercise (M): 8,400 @ $4.30 · Sale (S): 8,400 @ $10.10 · Option exercise (M): 43,883 @ $4.30 · Sale (S): 43,883 @ $10.10 · Option exercise (M): 8,400 @ $4.30 · Sale (S): 8,400 @ $10.15 · +12 more | EDGAR |
| 2025-06-06 | 4 | Hallal David — Director | Option exercise (M): 38,227 @ $4.30 · Sale (S): 38,227 @ $10.07 · Option exercise (M): 38,227 @ $4.30 · Sale (S): 38,227 @ $10.15 · Option exercise (M): 38,228 @ $4.30 · Sale (S): 38,228 @ $10.24 · +3 more | EDGAR |
| 2025-05-16 | 4 | EcoR1 Capital, LLC — 10% owner | Purchase (P): 1,658,978 @ $7.41 · Purchase (P): 3,300,000 @ $8 | EDGAR |
| 2025-05-15 | 4 | MPM BIOVENTURES 2018, L.P. MPM BioVentures 2018 LLC MPM BioVentures 2018 GP LLC | Sale (S): 630,191 @ $8.06 | EDGAR |
| 2025-05-15 | 4 | MPM BioVentures 2014, L.P. MPM BioVentures 2014 (B), L.P. MPM Asset Management Investors BV2014 LLC MPM BioVentures 2014 GP LLC MPM BioVentures 2014 LLC MPM BIOVENTURES 2018 (B), L.P. MPM ASSET MANAGEMENT INVESTORS BV2018 LLC EVNIN LUKE Foley Todd | Sale (S): 630,191 @ $8.06 | EDGAR |
| 2025-05-15 | 4 | GADICKE ANSBERT MPM BioImpact LLC Oncology Impact Fund (Cayman) Management L.P. UBS Oncology Impact Fund L.P. | Sale (S): 1,031,931 @ $8.06 | EDGAR |
| 2025-05-14 | 4 | Van Hauwermeiren Timothy — Director | Option exercise (M): 22,346 @ $4.30 · Option exercise (M): 22,346 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Call Matthew — Chief Operating Officer | Grant/award (A): 24,000 @ $0 · Grant/award (A): 145,000 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Detheux Michel — Chief Executive Officer | Grant/award (A): 77,000 @ $0 · Grant/award (A): 459,000 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | McGrath Yvonne — Chief Scientific Officer | Grant/award (A): 15,300 @ $0 · Grant/award (A): 91,000 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Gall Matthew — Chief Financial Officer | Grant/award (A): 24,000 @ $0 · Grant/award (A): 145,000 (derivative) @ $0 | EDGAR |
| 2024-12-06 | 4 | Feltquate David — Chief Medical Officer | Grant/award (A): 47,000 @ $0 | EDGAR |
| 2024-11-19 | 4 | Gall Matthew — Chief Financial Officer | Purchase (P): 5,000 @ $7.73 | EDGAR |
| 2024-08-09 | 4 | Detheux Michel — Chief Executive Officer | Gift (G): 442,800 (derivative) @ $0 · Gift (G): 442,800 (derivative) @ $0 | EDGAR |
| 2024-08-05 | 4 | Feltquate David — Chief Medical Officer | Grant/award (A): 350,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Van Hauwermeiren Timothy — Director | Grant/award (A): 24,200 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Lee David K — Director | Grant/award (A): 24,200 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | DeSimone Jill — Director | Grant/award (A): 24,200 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Iannone Robert — Director | Grant/award (A): 24,200 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Ho Tony W — Director | Grant/award (A): 24,200 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Davis Aaron I. — Director | Grant/award (A): 24,200 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Hallal David — Director | Grant/award (A): 24,200 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | RHOADS ANN D — Director | Grant/award (A): 24,200 (derivative) @ $0 | EDGAR |
| 2024-05-14 | 4 | RA CAPITAL MANAGEMENT, L.P. RA Capital Healthcare Fund LP Kolchinsky Peter Shah Rajeev M. | Other (J): 900,000 · Purchase (P): 5,714,285 (derivative) @ $17.50 · Other (J): 900,000 (derivative) | EDGAR |
| 2024-05-14 | 4 | Boxer Capital, LLC Boxer Asset Management Inc. LEWIS JOSEPH Davis Aaron I. — Director | Grant/award (A): 1,142,857 @ $17.50 | EDGAR |
| 2024-03-08 | 4 | Gall Matthew — Chief Financial Officer | Grant/award (A): 163,200 (derivative) @ $0 | EDGAR |
| 2024-03-08 | 4 | Call Matthew — Chief Operating Officer | Grant/award (A): 225,000 (derivative) @ $0 | EDGAR |
| 2024-03-08 | 4 | McGrath Yvonne — Chief Scientific Officer | Grant/award (A): 153,600 (derivative) @ $0 | EDGAR |
| 2024-03-08 | 4 | Detheux Michel — Chief Executive Officer | Grant/award (A): 590,400 (derivative) @ $0 | EDGAR |
| 2024-03-07 | 4 | DeSimone Jill — Director | Grant/award (A): 44,766 (derivative) @ $0 | EDGAR |
Recent 8-K events — iTeos Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-08-29 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-17 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-06-05 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-05-28 | 8-K | ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-05-13 | 8-K | 1.02 — Termination of a Material Definitive Agreement 7.01 — Regulation FD Disclosure | EDGAR |
| 2025-01-13 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2024-09-16 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2024-06-13 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ITOS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →